Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Profit After Tax: 2021-2025

Historic Profit After Tax for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $45.4 million.

  • SAB Biotherapeutics' Profit After Tax rose 539.11% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 141.13%. This contributed to the annual value of -$34.1 million for FY2024, which is 19.17% up from last year.
  • As of Q3 2025, SAB Biotherapeutics' Profit After Tax stood at $45.4 million, which was up 549.32% from -$10.1 million recorded in Q2 2025.
  • SAB Biotherapeutics' Profit After Tax's 5-year high stood at $45.4 million during Q3 2025, with a 5-year trough of -$22.9 million in Q4 2023.
  • In the last 3 years, SAB Biotherapeutics' Profit After Tax had a median value of -$7.3 million in 2024 and averaged -$4.2 million.
  • In the last 5 years, SAB Biotherapeutics' Profit After Tax slumped by 845.93% in 2023 and then surged by 539.11% in 2025.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Profit After Tax stood at -$11.6 million in 2021, then soared by 31.83% to -$7.9 million in 2022, then slumped by 190.26% to -$22.9 million in 2023, then spiked by 50.15% to -$11.4 million in 2024, then soared by 539.11% to $45.4 million in 2025.
  • Its last three reported values are $45.4 million in Q3 2025, -$10.1 million for Q2 2025, and -$5.2 million during Q1 2025.